# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Gilda Radner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML026-SYN
- Date: 2026-05-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Delia Marchand, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Review three weeks after cytoreductive surgery, on the first chemotherapy day. **S**

## History of present illness

Ms. Radner returns three weeks after primary cytoreductive surgery: hysterectomy with removal of both tubes and ovaries, total omentectomy, stripping of the right diaphragm, and excision of pelvic nodules, with no visible disease left. She went home on the fifth day. The wound has healed. She is giving herself enoxaparin each evening and will finish the 28 days next week; she has had no bleeding or leg swelling. She needed acetaminophen for two weeks and nothing now. Her appetite is back and the bloating has gone. Since surgery she has hot flashes several times a day and night sweats. She came this morning for her first cycle of carboplatin and paclitaxel. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Operation | Complete gross resection; home on day 5; wound healed |
| Pathology | High-grade serous carcinoma of both ovaries, pT3c, FIGO stage IIIC; serous tubal intraepithelial carcinoma in the right tube |
| Genetic results | Germline panel negative; tumor BRCA1 pathogenic variant; homologous recombination deficient |
| Symptoms | Bloating gone; appetite normal; new hot flashes and night sweats |
| Medicines | Enoxaparin, one week left; no pain medicine |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Night sweats with hot flashes; no fever; weight 55.2 kg |
| Gastrointestinal | Negative | No bloating, nausea or vomiting; bowels normal |
| Genitourinary | Negative | No urinary symptoms or vaginal bleeding |
| Neurological | Negative | No tingling or numbness in the hands or feet |
| Cardiovascular | Negative | No calf pain or leg swelling |
| Endocrine | Positive | Hot flashes several times a day since surgery |
| Psychiatric | Negative | Mood fair; PHQ-9 5; no thoughts of self-harm |

7 systems reviewed. **S**

## Current medications

- Enoxaparin 40 mg/0.4 mL prefilled syringe, 40 mg under the skin once daily for 28 days after surgery **S**
- Carboplatin 10 mg/mL injection, 610 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cycles **S**
- Paclitaxel 6 mg/mL injection, 275 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidine **S**
- Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea **S**

## Allergies

- No known allergy **S**

## Objective

BP 112/70 mmHg; pulse 84 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 55.2 kg; BMI 21.6 kg/m². All vital signs are synthetic.

Hemoglobin: 10.9 g/dL (low); White cell count: 6.9 10*3/uL; Absolute neutrophil count: 4.2 10*3/uL; Platelets: 356 10*3/uL; Creatinine: 0.68 mg/dL; eGFR: 114 mL/min/1.73 m²; ALT: 21 U/L; AST: 20 U/L; Total bilirubin: 0.4 mg/dL; Albumin: 3.7 g/dL; Magnesium: 1.9 mg/dL; CA-125: 188 U/mL (high); PHQ-9: 5; Pain, worst in the past week (0 to 10): 2. All results are synthetic.

## Change since baseline

- Hemoglobin: 12.4 g/dL at baseline, 10.9 g/dL (low) at this visit **S**
- White cell count: 7.8 10*3/uL at baseline, 6.9 10*3/uL at this visit **S**
- Platelets: 412 10*3/uL (high) at baseline, 356 10*3/uL at this visit **S**
- Creatinine: 0.72 mg/dL at baseline, 0.68 mg/dL at this visit **S**
- eGFR: 109 mL/min/1.73 m² at baseline, 114 mL/min/1.73 m² at this visit **S**
- ALT: 18 U/L at baseline, 21 U/L at this visit **S**
- AST: 22 U/L at baseline, 20 U/L at this visit **S**
- Total bilirubin: 0.5 mg/dL at baseline, 0.4 mg/dL at this visit **S**
- Albumin: 3.6 g/dL at baseline, 3.7 g/dL at this visit **S**
- CA-125: 1240 U/mL (high) at baseline, 188 U/mL (high) at this visit **S**
- Pain, worst in the past week (0 to 10): 5 at baseline, 2 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 112/70, pulse 84; weight 55.2 kg |
| Abdomen | Midline incision healed without redness or hernia; soft, non-tender; no fluid |
| Neurological | Light touch, pinprick and vibration normal in the hands and feet; ankle reflexes present (baseline before paclitaxel) |
| Extremities | No calf tenderness or swelling; injection sites on the abdomen clean |
| Psychiatric | Engaged and joking; organized |

All examination findings are synthetic. **S**

## Assessment and plan

1. **High-grade serous carcinoma of both ovaries, FIGO stage IIIC, after complete gross resection** (C56.3). Surgery achieved the best outcome, no visible residual disease. Pathology confirms stage IIIC. The germline panel is negative, so there is no inherited variant to pass on; the tumor carries a BRCA1 pathogenic variant that arose in the tumor and is homologous recombination deficient. If she responds to chemotherapy, maintenance with a PARP inhibitor is recommended. CA-125 has fallen from 1240 to 188. Hepatitis B, hepatitis C and HIV tests were negative. Blood counts, kidney and liver function, and magnesium allow full-dose treatment: creatinine 0.68 mg/dL, estimated creatinine clearance about 97 mL/min. **S**
   - Cycle 1 of carboplatin AUC 5 (610 mg) and paclitaxel 175 mg/m2 (275 mg) today, every 21 days for six cycles.
   - Fosaprepitant, palonosetron and dexamethasone before each cycle; ondansetron at home as needed.
   - Temperature twice a day for a week after each cycle; call at once for 38.0 °C or more.
   - Finish enoxaparin next week.
2. **Family history of ovarian cancer** (Z80.41). Her own germline result is negative. The genetic counselor advised that, because three relatives had ovarian cancer and none was tested, her blood relatives may still benefit from their own genetic counseling; a negative result in her does not rule out an inherited cause in the family. **S**
   - Copy of the result and the counselor's letter for her to share as she chooses.
3. **Symptomatic surgical menopause** (E89.41). Hot flashes and night sweats since both ovaries were removed at 39. Hormone therapy is not ruled out by high-grade serous cancer and will be discussed at the end of treatment; for now non-hormonal measures. **S**
   - Layered clothing, a fan, and cooling bedding.
   - Revisit at each visit; bone density scan after treatment.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Surgical pathology and stage | After surgery | Up to date | High-grade serous carcinoma, pT3c, FIGO stage IIIC; no visible residual disease |
| Laboratory | Germline multigene panel | Once, at diagnosis | Completed today | Reviewed with her: no pathogenic variant in BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 or the Lynch syndrome genes |
| Laboratory | Tumor testing for BRCA1 and BRCA2 and homologous recombination deficiency | On the surgical specimen, before the maintenance decision | Completed today | Tumor BRCA1 pathogenic variant (somatic, as the germline test is negative); homologous recombination deficient |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before chemotherapy | Up to date | All negative; no antiviral prophylaxis needed |
| Laboratory | Blood count with neutrophils and platelets | Before each chemotherapy cycle | Completed today | Hemoglobin 10.9 g/dL after surgery, white cells 6.9, neutrophils 4.2, platelets 356 |
| Laboratory | Creatinine and estimated kidney function (carboplatin dose) | Before each cycle | Completed today | Creatinine 0.68 mg/dL, eGFR 114; carboplatin 610 mg for AUC 5 |
| Laboratory | Liver tests (paclitaxel) | Before each cycle | Completed today | ALT 21, AST 20 U/L, bilirubin 0.4 mg/dL, albumin 3.7 g/dL |
| Laboratory | Magnesium | Before each cycle | Completed today | 1.9 mg/dL |
| Laboratory | CA-125 | At diagnosis; before each cycle when raised at diagnosis; at the end of treatment; then at each surveillance visit | Completed today | 188 U/mL, from 1240 before surgery |
| Examination | Peripheral neuropathy: symptoms and examination | At baseline and before each taxane cycle | Completed today | Baseline normal before the first paclitaxel dose |
| Medication safety | Nausea and vomiting control | Each cycle | Completed today | Three-drug preventive regimen for carboplatin (an NK1 antagonist, a 5-HT3 antagonist and dexamethasone); ondansetron at home |
| Medication safety | Paclitaxel infusion reaction prevention | Each paclitaxel dose | Completed today | Dexamethasone, diphenhydramine and famotidine before the infusion; first-hour observation |
| Medication safety | Thromboprophylaxis after cancer surgery | From surgery for four weeks | Completed today | Day 22 of 28 of enoxaparin; no bleeding or leg swelling |
| Examination | Wound review | After surgery | Completed today | Healed, without hernia |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, at each treatment phase, and when symptoms change | Completed today | PHQ-9 5; no thoughts of self-harm |
| Survey | Pain score | Each visit after surgery | Completed today | Worst pain 2 of 10; no pain medicine |
| Self-management | Menopausal symptoms after oophorectomy | Each visit after surgery | Completed today | Hot flashes several times a day and night sweats; non-hormonal measures |
| Self-management | Psychosocial support and information | At diagnosis and throughout | Completed today | Joined a cancer support community group last week |

## Goal progress

- Tissue diagnosis and gynecologic oncology plan within two weeks of presentation. Outcome by 2026-04-14: Ultrasound, CT and biopsy within four days; diagnosis and consultation on the eighth day. **S**
- Cytoreductive surgery with no visible residual disease within three weeks of diagnosis. Outcome by 2026-05-12: Complete gross resection one week after the diagnosis. **S**
- Six cycles of carboplatin and paclitaxel every three weeks without a delay of more than one week. In progress; target 2026-09-15. **S**
- Germline and tumor genetic results available before the maintenance decision. In progress; target 2026-09-15. **S**
- PHQ-9 below 10 throughout treatment, with a peer-support connection. In progress; target 2026-09-15. **S**

## Medication changes

- Started: Carboplatin 10 mg/mL injection, 610 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cycles **S**
- Started: Paclitaxel 6 mg/mL injection, 275 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidine **S**
- Started: Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026), National Comprehensive Cancer Network
- Konstantinopoulos PA, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol 2020;38(11):1222-1245 (2020), American Society of Clinical Oncology
- Tew WP, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol 2020;38(30):3468-3493 (2020), American Society of Clinical Oncology
- Salani R, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146(1):3-10 (2017), Society of Gynecologic Oncology
- Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (2023), American Society of Clinical Oncology
- Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (2020), American Society of Clinical Oncology
- Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020), American Society of Clinical Oncology
- Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020 (2020), American Society of Clinical Oncology
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Cycles every 21 days in the infusion center. Primary care and gynecologic oncology review at cycle 4. Call at once for a temperature of 38.0 °C or more. **S**
- Next scheduled visit 2026-07-14: midpoint of chemotherapy: CA-125, blood counts, neuropathy, and menopausal symptoms. **S**
